Ascendis Pharma unveils its second TransCon™ offering: YORVIPATH® hits markets in Germany and Austria, targeting chronic hypoparathyroidism in adults.

Cefdinir, marketed under the brand name Omnicef, is a small molecule drug that acts as a penicillin-binding protein (PBP) inhibitor and a cell wall inhibitor.

NeuroBo Pharmaceuticals has received approval from the FDA for a Phase 1 clinical study of DA-1726, a new drug aimed at managing obesity.

Fluconazole is a small molecule drug used to treat various fungal infections. It is sold under the trade names Diflucan, Zoltec, and Loitin.

Halia Therapeutics has unveiled a $30 million Series C funding round to further develop their innovative range of treatments for inflammation.

Meclizine is a small molecule drug that acts as an antagonist of histamine (H1) receptors.

Bio-Thera Solutions has launched an early-stage clinical study, specifically Phase 1B/2A, for its novel monoclonal antibody, BAT6026, aimed at OX40 for treating individuals experiencing moderate to intense eczema.

Rosuvastatin, sold as Ezallor and Crestor, is a small molecule inhibiting liver cholesterol synthesis by blocking HMG-CoA reductase enzyme.

Recent findings on Genentech's drug Vabysmo indicate persistent efficacy in reducing retinal swelling and enhancing eyesight for those with Retinal Vein Occlusion.

Escitalopram, marketed under the trade name Esertia, is an orally administered selective serotonin reuptake inhibitor.

RS Oncology Confirms Initial Participant Receives Dosage in Stage 2 Trial (MITOPE) Examining RSO-021 in Malignant Chest Tumor and Lung Metastases Therapy.

Ketamine is a small molecule drug that acts as a modulator at the N-methyl-D-aspartate (NMDA) receptor.